US alliance to accelerate next‑generation oral monoclonal antibody therapies Liège, Belgium, and Roanoke (VA), USA, March 18, ...
Strategic US-EU alliance combines high-yield mAb production with industrial-scale exosome loading to eliminate the need for ...
Liège-based Bio‑Sourcing and Roanoke-based The Tiny Cargo Company inked a strategic collaboration to co‑develop orally delivered monoclonal antibody (mAb)-based therapies formulated using goat ...
The respiratory illness RSV is still going strong in Chicago – an unusually late showing for the virus, which can strike ...
The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward ...
The biomarker data presented at AD/PD 2026 from the Phase III APOLLOE4 trial showed that in the MCI subgroup, ...
A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...
CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today ...
Some respiratory viruses, especially RSV, are seeing a late winter to early spring surge in Wisconsin, public health experts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results